World's Best Scientists 2026 revealed!
Jerald C. Sadoff

Jerald C. Sadoff

Award Badge
Immunology
Belgium
2026

D-Index & Metrics

Immunology

D-Index
92
Citations
34323
World Ranking
1001
National Ranking
8

Medicine

D-Index
92
Citations
34344
World Ranking
11225
National Ranking
135

Jerald C. Sadoff publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jerald C. Sadoff sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 271 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jerald C. Sadoff D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jerald C. Sadoff sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 92 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in Belgium Leader Award
  • 2025 - Research.com Immunology in Belgium Leader Award

Overview

Jerald C. Sadoff is affiliated with Janssen in Belgium and has an extensive research profile primarily in the field of Medicine. Their work focuses significantly on Infectious Diseases, with notable contributions to Epidemiology, Immunology, Molecular Biology, and Genetics as subfields of study.

The main topics central to their research include:

  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • Respiratory viral infections research
  • Vaccines and immunoinformatics approaches
  • Virus-based gene therapy research
  • Influenza Virus Research Studies
  • Vaccine Coverage and Hesitancy

Jerald C. Sadoff has contributed to several peer-reviewed journals and publication venues, frequently appearing in the following:

  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Vaccine
  • Open Forum Infectious Diseases
  • UNC Libraries

Some of their recent papers include:

  • Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19, 2021, New England Journal of Medicine
  • Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine, 2021, New England Journal of Medicine
  • Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans, 2021, Nature
  • Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19, 2021, JAMA
  • Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination, 2021, New England Journal of Medicine

In terms of collaboration, Jerald C. Sadoff frequently co-authors with several researchers including:

  • Mathieu Le Gars
  • Macaya Douoguih
  • Hanneke Schuitemaker
  • Frank Struyf
  • Carla Truyers

Best Publications

  • Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.

    Jerald Sadoff;Glenda Gray;An Vandebosch;Vicky Cárdenas

  • Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

    Ziegler Ej;Fisher Cj;Sprung Cl;Straube Rc

  • Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein

    Charles J. Fisher;Jan M. Agosti;Steven M. Opal;Stephen F. Lowry

  • Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

    Fisher Cj;Dhainaut Jf;Opal Sm;Pribble Jp

  • Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a Mutant Escherichia coli

    Ziegler Ej;McCutchan Ja;Fierer J;Glauser Mp

  • Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

    Jerald Sadoff;Mathieu Le Gars;Georgi Shukarev;Dirk Heerwegh

  • Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

    Steven M. Opal;Charles J. Fisher;Jean-Francois A. Dhainaut;Jean-Louis Vincent

  • Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis

    Charles J. Fisher;S.M. Opal;Jean-Francois Dhainaut;S Stephens

  • Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

    Dan H. Barouch;Dan H. Barouch;Jinyan Liu;Hualin Li;Lori F. Maxfield

  • Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization

    Donata R. Sizemore;Arthur A. Branstrom;Jerald C. Sadoff

  • Advances in tuberculosis vaccine strategies.

    Yasir A. W. Skeiky;Jerald C. Sadoff

  • Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

    D. M. Gordon;T. W. McGovern;U. Krzych;J. C. Cohen

  • Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria.

    JC Sadoff;WR Ballou;LS Baron;WR Majarian

  • Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

    Unknown

  • Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

    Dan H Barouch;Dan H Barouch;Frank L Tomaka;Frank Wegmann;Daniel J Stieh

  • Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.

    Terhi Kilpi;Heidi Åhman;Jukka Jokinen;Kari S. Lankinen

  • Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults

    Dani Cohen;Dani Cohen;Shai Ashkenazi;Shai Ashkenazi;Manfred S Green;Manfred S Green;Michael Gdalevich

  • The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat.

    Kwang Sik Kim;Hideo Itabashi;Peter Gemski;Jerald Sadoff

  • Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection.

    A S Cross;J C Sadoff;N Kelly;E Bernton

  • Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria

    Christian F. Ockenhouse;Pei Fang Sun;David E. Lanar;Bruce T. Wellde

  • Use of Azithromycin for the Treatment of Campylobacter Enteritis in Travelers to Thailand, an Area Where Ciprofloxacin Resistance Is Prevalent

    Robert A. Kuschner;Andrew F. Trofa;Richard J. Thomas;Charles W. Hoge

  • Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.

    Galit Alter;Galit Alter;Jingyou Yu;Jinyan Liu;Abishek Chandrashekar

Frequent Co-Authors

Alan S. Cross
Alan S. Cross University of Maryland, Baltimore
Stanley J. Cryz
Stanley J. Cryz University of Massachusetts Chan Medical School
David N. Taylor
David N. Taylor Johns Hopkins University
Steven M. Opal
Steven M. Opal Brown University
Barbara H. Iglewski
Barbara H. Iglewski University of Rochester
Dan H. Barouch
Dan H. Barouch Harvard Medical School
Hanneke Schuitemaker
Hanneke Schuitemaker Valneva (Austria)
Willem A. Hanekom
Willem A. Hanekom University College London
Jaap Goudsmit
Jaap Goudsmit Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Programs like Licensed Practical Nurse (LPN) paths often serve as entry points into the medical field, and those looking for less stringent admissions may find the lpn programs with easiest admission requirements particularly appealing. These programs provide foundational patient care skills that complement immunological knowledge.

Advancing further, many pursue Nurse Practitioner degrees that combine clinical expertise with specialized practice. The easiest nurse practitioner program options can help professionals transition smoothly, balancing coursework and practical experience.

Specialties such as psychiatric mental health nurse practitioner (PMHNP) programs integrate immunological studies with mental health, often featuring robust clinical placement opportunities. Interested students should consider the best pmhnp programs to maximize hands-on experience and career readiness.

Cost is also crucial when selecting a program. Fortunately, several affordable options exist, and exploring the cheapest psych np programs can reduce financial barriers while ensuring quality education in psychiatric nursing aligned with immunological principles.

Best Scientists Citing Jerald C. Sadoff

Trending Scientists

Recently Published Articles